Pediatrix Medical Group, Inc. (MD) AI Stock Analysis

Pediatrix Medical Group, Inc., formerly known as MEDNAX, Inc., delivers newborn, maternal-fetal, pediatric cardiology, and related pediatric subspecialty care across the United States and Puerto Rico. Its offerings center on neonatal care within dedicated hospital units for premature infants or those with complications, delivered by neonatal physician subspecialists and nurse practitioners. The company also provides maternal-fetal care for expectant mothers and unborn babies across both inpatient and office environments. Additionally, Pediatrix manages pediatric cardiology services for patients ranging from fetuses to adolescents with congenital or acquired heart conditions, operating a clinical network of approximately 2,700 physicians as of February 2022.

Pediatrix recorded a 5-year revenue CAGR of 2.0% from FY2020 to FY2025. Annual revenue grew to $1.97B in FY2022, $1.99B in FY2023, and $2.01B in FY2024 before decreasing 4.9% to $1.91B in FY2025. After net losses of -$60.4M in FY2023 and -$99.1M in FY2024, profitability rebounded in FY2025 with net income of $165.4M and an operating margin of 12.1%. For the trailing twelve months, revenue was $1.95B and diluted EPS was $2.09. In the latest quarter ended June 30, 2026, quarterly revenue grew 4.0% year-over-year while quarterly earnings expanded 6.5%.

As of June 30, 2026, Pediatrix held $404.2M in cash and short-term investments alongside total debt of $620.0M, resulting in net debt of $215.8M. Total assets stood at $2.13B against shareholders' equity of $881.0M, with a current ratio of 1.32 and a debt-to-equity ratio of 0.70. Operating cash flow reached $271.1M in FY2025. The company deployed cash toward $18.5M in capital expenditures and $86.7M in share buybacks during FY2025, contributing to a 5-year share count decline of -5.8%.

Pediatrix trades at a trailing P/E of 13.1x and a forward P/E of 9.3x, both below the US-listed Healthcare median of 24.6x trailing and 17.3x forward. Its enterprise value to EBITDA ratio is 8.2x compared to the peer median of 12.0x, while its price-to-sales ratio sits at 1.1x versus the peer median of 4.1x. Over the past year, the stock returned 69.0%, outpacing the S&P 500 return of 16.8%. Over a 5-year period, MD gained 4.3% compared to an 83.0% return for the benchmark.

Wall Street coverage includes 1 Strong Buy and 6 Hold ratings. The mean price target is $26.33, which is 3.8% below the last closing price of $27.38. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $1.96B and EPS of $2.35, representing 15.1% annual EPS growth. For the following fiscal year, 6 analysts forecast revenue of $2.01B and EPS of $2.44. MD has beaten EPS estimates in 3 of the last 4 quarters, with the next earnings release scheduled for November 2, 2026.

This page is an AI-written research summary of Pediatrix Medical Group, Inc. (MD). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: MD income statement, MD balance sheet, MD key metrics, MD analyst forecast, MD chart. See the MD stock overview for the latest quote and news.